Red blood cell immunization as an independent predictor of survival in the myelodysplastic syndromes
British Journal of Haematology · 2026
DOI: 10.1111/bjh.70330 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Alexandra Pedraza und 7 weiteren Autor:innen. Beteiligte Einrichtung: Banc de Sang i Teixits-Hospital Clínic, Barcelona, Spain. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Erythrocytes, Erythrocyte Transfusion. Die Arbeit nennt 35 Literaturangaben.
Abstract (Originalsprache)
Despite red blood cell (RBC) immunization being a frequent complication of chronic transfusion in myelodysplastic syndromes (MDS), its prognostic significance remains unclear. We analysed 486 transfused patients diagnosed with MDS. Prognostic impact of RBC immunization (allo‐ or autoantibodies) was evaluated as a time‐dependent covariate. Competing risk methods were applied to estimate the cumulative incidence of immunization. Sixty‐nine patients (14.2%) developed RBC immunization, most commonly anti‐K and anti‐E, which was more frequent in patients transfused before MDS diagnosis (subhazard ratio [SHR]: 2.9, 95% confidence interval [CI]: 1.6–5.4; p = 0.001) and Rh(D)‐negative blood group (SHR: 1.9, 95% CI: 1.1–3.2; p = 0.026). RBC immunization was associated with a significant and independent reduction in remaining survival (hazard ratio: 11.9, 95% CI: 7.3–19.6; p = 0.001), without differences between auto‐ and alloantibodies. RBC immunization was followed by increased transfusion intensity, but transfusion requirements also rose in non‐immunized patients over time. RBC immunization did not predict progression to acute myeloid leukaemia (AML). A trend towards fewer new antibodies was observed during hypomethylating therapy. RBC immunization is independently associated with reduced survival in transfusion‐dependent patients with MDS, irrespective of AML progression. These findings highlight the potential prognostic relevance of RBC antibodies and call for further investigation into the mechanisms linking immunization, transfusion burden and survival outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Banc de Sang i Teixits-Hospital Clínic, Barcelona, Spain.
- Hematopathology Section, Department of Pathology, Center for Biomedical Diagnosis, Hospital Clínic, Barcelona, Spain.
- Transfusion Service, Center for Biomedical Diagnosis, Hospital Clínic, Barcelona, Spain.
- Section of Hemostasis, Cancer and Hematology Diseases Institute, Hospital Clínic, Barcelona, Spain.
- Information Systems, Center for Biomedical Diagnosis, Hospital Clínic, Barcelona, Spain.
- Hematology Department, Hospital Clínic, Barcelona, Spain.
ORCID-Profile: Cristina Sanz
Zitieren
APA
Pedraza, A., Castaño, S., Pereira, A., Nomdedeu, M., Ruiz, C., Esteva, M., Díaz-Beya, M., & Sanz, C. (2026). Red blood cell immunization as an independent predictor of survival in the myelodysplastic syndromes. British Journal of Haematology. https://doi.org/10.1111/bjh.70330
Vancouver
Pedraza A, Castaño S, Pereira A, Nomdedeu M, Ruiz C, Esteva M, et al. Red blood cell immunization as an independent predictor of survival in the myelodysplastic syndromes. British Journal of Haematology. 2026. doi:10.1111/bjh.70330
BibTeX
@article{Pedraza2026,
author = {Pedraza, Alexandra and Castaño, Sandra and Pereira, Arturo and Nomdedeu, Meritxell and Ruiz, Carlos and Esteva, Marc and Díaz-Beya, Marina and Sanz, Cristina},
title = {Red blood cell immunization as an independent predictor of survival in the myelodysplastic syndromes},
journal = {British Journal of Haematology},
year = {2026},
doi = {10.1111/bjh.70330}
}
EUVIMED